Reference:
1. European Medicines Agency. New restrictions to minimise the risks of effects on heart rhythm with hydroxyzine-containing medicines, 2015. Available from: https://www.ema.europa.eu/en/news/new-restrictions-minimise-risks-effects-heart-rhythm-hydroxyzine-containing-medicines.
2. Schlit AF, Delaunois A, Colomar A, Claudio B, Cariolato L, Boev R, et al. Risk of QT prolongation and torsade de pointes associated with exposure to hydroxyzine: re-evaluation of an established drug. Pharmacol Res Perspect 2017;5(3):e00309.
3. Guaiana G, Barbui C, Cipriani A. Hydroxyzine for generalised anxiety disorder. Cochrane Database Syst Rev 2010;(12):CD006815.
4. Hydroxyzine hydrochloride. Product information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/088617Orig1s043,088618Orig1s043,088619Orig1s044lbl.pdf
Keywords:
-